ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 3

1 participants needed

1 Location

Brief description of study

This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with bypassing agents, as determined by the frequency of bleeding episodes in enrolled adult subjects who are who have hemophilia A or B with an inhibitor who are not on prophylaxis.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Hemophilia
Age: 99 years or below
Gender: All

Updated on 19 Feb 2024. Study ID: 830125

Find a site

Your Information has been sent successfully.

Message sent successfully.

We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.

If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

ALN-AT3SC-003: ATLAS INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B with Inhibitory Antibodies to Factor VIII or IX

Brief description of study

Eligibility of study

Find a site